Get the Stockscreener App
5.37
10.20%
-0.61
After Hours:
5.35
-0.02
-0.37%
Leonabio Inc stock is traded at $5.37, with a volume of 121.50K.
It is down -10.20% in the last 24 hours and up +12.11% over the past month.
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
See More
Previous Close:
$5.98
Open:
$5.6259
24h Volume:
121.50K
Relative Volume:
4.11
Market Cap:
$50.13M
Revenue:
-
Net Income/Loss:
$-37.72M
P/E Ratio:
-0.7112
EPS:
-7.5501
Net Cash Flow:
$-52.35M
1W Performance:
-4.45%
1M Performance:
+12.11%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.36
$6.06
1-Week Range:
$5.05
$6.10
52-Week Range:
$4.21
$6.625
Leonabio Inc Stock (LONA) Company Profile
Name
Leonabio Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
5.37 | 55.83M | 0 | -37.72M | -52.35M | -7.5501 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Leonabio Inc Stock (LONA) Latest News
Athira Pharma (LONA) 10K Form and SEC Filings 2026 $LONA - MarketBeat
Cantor Fitzgerald initiates Leona Bio stock with overweight rating By Investing.com - Investing.com Australia
LeonaBio initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald Initiates Coverage on LeonaBio With Overweight Rating - marketscreener.com
LONA Technical Analysis & Stock Price Forecast - Intellectia AI
LONA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LeonaBio, Inc. (prev. ATHA) (LONA) Stock Price Today | Live Chart & News - Traders Union
LeonaBio Shares Rise After Mizuho Securities Upgrade - marketscreener.com
LeonaBio (LONA) Receives Upgrade to Outperform by Mizuho | LONA Stock News - GuruFocus
Mizuho Securities Upgrades LeonaBio to Outperform From Neutral, Price Target is $4 - marketscreener.com
Mizuho upgrades LeonaBio stock rating on breast cancer drug potential By Investing.com - Investing.com India
Mizuho upgrades LeonaBio stock rating on breast cancer drug potential - Investing.com
Mizuho Securities Initiates LeonaBio(LONA.US) With Buy Rating, Announces Target Price $10 - 富途牛牛
LeonaBio (ATHA) proxy asks investors to back warrant share issuances and 2026 equity plan - stocktitan.net
LeonaBio appoints Mark Kubik as chief business officer By Investing.com - Investing.com Nigeria
Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer - marketscreener.com
LeonaBio (LONA) Names Mark Kubik as New Chief Business Officer - GuruFocus
LeonaBio appoints Mark Kubik as chief business officer - Investing.com
LeonaBio, Inc. Appoints Mark F. Kubik as Chief Business Officer to Drive Business Development Strategy - Quiver Quantitative
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - marketscreener.com
Biopharma deal veteran to drive LeonaBio’s Phase 3 breast cancer drug - Stock Titan
Leonabio Inc files for offering of up to 58.5 million shares of common stock by the selling stockholders - marketscreener.com
Leonabio Inc Files For Offering Of Up To 58.5 Million Shares Of Common Stock By The Selling Stockholders - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" - Investing News Network
LONA Stock Price and Chart — NASDAQ:LONA - TradingView
Athira Pharma (ATHA) Options to Be Delisted on January 12th - GuruFocus
LONA Stock Price, News & Analysis - Stock Titan
Athira Pharma Rebrands as LeonaBio, Refocusing on Oncology - TipRanks
Athira Pharma announces name change to LeonaBio - TipRanks
Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma
Athira Pharma changes name, ticker symbol - MSN
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy - Investing.com Nigeria
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy By Investing.com - Investing.com South Africa
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Athira Pharma (NASDAQ: ATHA) posts $6.6M Q3 loss; ATH-1105 study shows favorable safety, CNS penetration - Stock Titan
Athira Pharma announces reverse stock split - marketscreener.com
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - GlobeNewswire
ATHA SEC FilingsAthira Pharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
ATHA Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan
Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st
ATHA Stock Price, News & Analysis - stocktitan.net
Athira Pharma's ALS Drug Shows Promising Neuroprotective Effects in Key Preclinical Study - Stock Titan
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - marketscreener.com
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology - marketscreener.com
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference - Stock Titan
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND - marketscreener.com
Athira Pharma, Inc. Plans to Further Extend the Current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD Trials - marketscreener.com
Athira Pharma Provides 2023 Pipeline Outlook - marketscreener.com
Leonabio Inc Stock (LONA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Leonabio Inc Stock (LONA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| San Martin Javier | CHIEF MEDICAL OFFICER |
Dec 31 '25 |
Option Exercise |
0.00 |
4,667 |
0 |
11,833 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jan 02 '26 |
Sale |
6.88 |
1,644 |
11,311 |
10,189 |
| Litton Mark James | President and CEO |
Dec 31 '25 |
Option Exercise |
0.00 |
10,834 |
0 |
43,414 |
| Litton Mark James | President and CEO |
Jan 02 '26 |
Sale |
6.88 |
2,586 |
17,792 |
40,828 |
| Renninger Robert | Chief Financial Officer |
Dec 31 '25 |
Option Exercise |
0.00 |
1,236 |
0 |
13,154 |
| Renninger Robert | Chief Financial Officer |
Jan 02 '26 |
Sale |
6.88 |
297 |
2,043 |
12,857 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Dec 31 '25 |
Option Exercise |
0.00 |
3,667 |
0 |
21,557 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jan 02 '26 |
Sale |
6.88 |
876 |
6,027 |
20,681 |
| Worthington Mark | General Counsel and CCO |
Dec 31 '25 |
Option Exercise |
0.00 |
3,667 |
0 |
14,854 |
| Worthington Mark | General Counsel and CCO |
Jan 02 '26 |
Sale |
6.88 |
876 |
6,027 |
13,978 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):